Women with greater baseline urge incontinence symptoms, those with more advanced pelvic organ prolapse, and postmenopausal women not on hormone replacement therapy (HRT) are all at greater risk for treatment failure when undergoing Burch and sling procedures for stress urinary incontinence.
Pembrolizumab/axitinib efficacy in ccRCC sustained at 5-year follow-up
June 6th 2023At a median follow-up of 67.2 months, the combination of pembrolizumab and axitinib continued to show an overall survival and progression-free survival benefit over sunitinib monotherapy in the first-line setting.
2 Clarke Drive
Cranbury, NJ 08512